{"disease":{"id":"progressive-pulmonary-fibrosis","name":"Progressive Pulmonary Fibrosis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":3},"drugs":{"marketed":[{"drug_id":"nerandomilast","indication_name":"Progressive Pulmonary Fibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jascayd","generic_name":"NERANDOMILAST","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Jascayd works by inhibiting the activity of phosphodiesterase 4, an enzyme involved in the inflammatory response."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06238622","title":"A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1700,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT06025578","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1057,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT07503587","title":"Evaluating the Efficacy and Safety of of HSK44459 in People With Progressive Pulmonary Fibrosis","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":378,"lead_sponsor_name":"Haisco Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT06951217","title":"An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":340,"lead_sponsor_name":"Avalyn Pharma Inc.","has_results":false},{"nct_id":"NCT03939520","title":"Management of Progressive Disease in Idiopathic Pulmonary Fibrosis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":279,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT07269262","title":"SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers","phase":"NA","overall_status":"RECRUITING","enrollment_count":170,"lead_sponsor_name":"Medical University of South Carolina","has_results":false},{"nct_id":"NCT07486206","title":"Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":152,"lead_sponsor_name":"Hospital de Granollers","has_results":false},{"nct_id":"NCT07466420","title":"Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Katerina M. Antoniou","has_results":false},{"nct_id":"NCT06360094","title":"A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":85,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT05241275","title":"Xenon MRI and Progressive ILD","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT04837131","title":"A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Michael M. Pham","has_results":true}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}